180 / 510
Cuidados
Continuos
179
BIBLIOGRAFÍA
Floyd JD, Nguyen DT, Lobins RL et al. Cardiotoxicity of Cancer Therapy. J Clin Oncol. 2005 Oct
20;23(30):7685-96.
Smith LA, Cornelius VR, Plummer CJ et al. Cardiotoxicity of anthracycline agents for the treatment of
cancer: Systematic review andmeta-analysis of randomised controlled trials. BMCCancer. 2010 Jun
29;10:337.
Lipshultz SE, Scully RE, Lipsitz SR et al. Assessment of dexrazoxane as a caridioprotectant in
doxorubicin-treated childrenwith high-risk acute lymphoblastic leukaemia: long-term follow-up of a
prospective, randomised, multicentre trial. Lancet Oncol. 2010 Oct;11(10):950-61.
Tebbi CK, LondonWb, Friedman D et al. Dexrazosane-Associated Risk for AcuteMyeloid Leukemia/
Myelodysplastic Syndrome and Other SecudaryMalignancies in Pediatric Hodkin’s Disease. J Clin Oncol.
2007 Feb 10;25(5):493-500.
D’Ortencio A y Navigante A. Insuficiencia cardíaca relacionada a quimioterapia. Nuevo enfoque.
Insuficiencia Cardíaca. 2006;1(1):28-32.
Gianni L, Herman EH, Lispshultz SE et al. Anthracycline Cardiotoxicity: FromBench to Bedside. J Clin
Oncol. 2008 Aug 1;26(22):3777-84.
NysomK, HolmK, Lipsitz SR et al. Relationship Between Cumulative Anthracycline Dose and Late
Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia. J Clin Oncol. 1998 Feb;16(2):545-50.
Pinder MC, Duan Z, Goodwin JS et al. Congestive Heart Failure in OlderWomen TreatedWith Adjuvant
Anthracycline Chemotherapy for Breast Cancer. J Clin Oncol. 2007 Sep 1;25(25):3808-15.
Carver JR, Shapiro CL, Ng A, et al. American Society of Clinical Oncology Clinical Evidence Review on
the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects. J Clin Oncol. 2007 Sep
1;25(25):3991-4008.
Gietema JA, Sleijfer DT, Willemse PH et al. Long-term follow-up of cardiovascular risk factors in patients
given chemotherapy for disseminated nonseminomatous testicular cancer. Ann InternMed. 1992May
1;116(9):709-15.
Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular Morbidity in Long - TermSurvivors of
Metastatic Testicular Cancer. J Clin Oncol. 2000 Apr;18(8):1725-32.
GoldbergMA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis as a
risk factor. Blood 1986;68: 1114-8
Yeh ET, Bickford CL, Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis
andmanagement. J AmCOll Cardiol 2009;53:2231-47
Harris EE, Correa C, HwangWT et al. Late CardiacMortality andMorbidity in Early-Stage Breast Cancer
Patients After Breast-Conservation Treatment. J Clin Oncol. 2006 Sep 1;24(25):4100-6.
Darby SC, McGale P, Taylor CWet al. Long-termmortality fromheart disease and lung cancer after
radiotherapy for early breast cancer: prospective cohort study of about 300,000 women inUS SEER
cancer registries. Lancet Oncol. 2005 Aug;6(8):557-65.
Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic
Implications of Troponin I Elevation. J Clin Oncol. 2010 Sep 1;28(25):3910-6.
Telli ML, Hunt SA, Carlson RWet al. Trastuzumab-Related Cardiotoxicity: Calling Into Question the
Concept of Reversibility. J Clin Oncol. 2007 Aug 10;25(23):3525-33.
O’Sullivan JM, Huddart RA, Norman AR et al. Predicting the risk of bleomycin lung toxicity in patiens with
germ-cell tumors. Ann Oncol. 2003 Jan; 14(1):91-6.
Sleijfer S. Bleomycin-induced pneumonitis. Chest. 2001 Aug;120(2):617-24.
Montero A, Hervás A, Morera R y cols. Control de síntomas crónicos. Efectos secundarios del
tratamiento con Radioterapia y Quimioterapia. Oncología 2005;28(3):147-156.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.